|Outcomes at 2–24 weeks (number of studies)||Weighted mean difference (95% CI)|
|Morning peak expiratory flow (l/min) (n=8)||33 (25 to 41)|
|Evening peak expiratory flow (l/min) (n=8)||26 (18 to 33)|
|Forced expiratory volume in 1 second (l) (n=8)||0.23 (0.14 to 0.31)|
|Daytime asthma symptom score (n=3)||−0.15 (−0.23 to −0.06)|
|Night time asthma symptom score (n=3)||−0.21 (−0.31 to −0.10)|
|Percentage of days without symptoms (n=2)||10 (2 to 19)|
|Percentage of nights without symptoms (n=3)||12 (8 to 16)|
|Daytime use of rescue bronchodilators (puffs/24 h) (n=4)||−0.33 (−0.50 to −0.16)|
|Night time use of rescue bronchodilators (puffs/24 h) (n=4)||−0.31 (−0.43 to −0.19)|
Review: regular inhaled long acting β2 agonists are associated with better outcomes than short acting β2 agonists in adults and children with chronic asthma
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>
EBN Online Journal Club
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.